Build community with your colleagues in our new space for knowledge exchange and professional networking.
Connect
Build a knowledge base of industry best practices, sample documents and more in our resource library.
Learn
Ask questions of your peers to gain the tools you need to communicate with leaders and partners in your field.
Explore
We were expecting a lot of phone calls after the media picked up the BMJ study results (like after the FDA mesh situations)- but not so much. Since the AUGS position paper, we have been trying to counsel and slowly move people off anti-cholinergics when ...
We had an abbreviated discussion previously when the BMJ study was published. My concern is that they should highlight the most concerning finding. In the past, our take home message has always been to avoid anticholinergics in the "at risk" population. ...
AUGS has a very helpful consensus statement from 2017, But given the BMJ article that came out in 2018 and now this JAMA article, I am wondering if we need to move away from anticholinergics as chronic therapy altogether. It also concerns me that BOTOX ...